Document Detail

Two-day thionamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves' disease.
MedLine Citation:
PMID:  16896267     Owner:  NLM     Status:  MEDLINE    
The appropriate period of antithyroid drug (ATD) discontinuation before radioiodine therapy is the most critical problem in Graves' disease patients under going treatment with ATD. To determine the optimal period that does not alter the outcome of radioiodine therapy or exacerbate hyperthyroidism, we compared serum FT4 levels at radioiodine uptake (RAIU) and therapy outcomes between a 2-day withdrawal group and 7-day withdrawal group. We prospectively recruited 43 patients for the 2-day withdrawal protocol and retrospectively reviewed 49 patients treated with radioiodine following the protocol of 7-day withdrawal. There was no significant difference in RAIU between the 2 groups. The mean serum FT4 level measured on the first day of 24-h RAIU of the 7-day group was significantly higher than that in the 2-day group. There were no significant differences in the outcomes at each point (6 months, 1 year, and 2 years after therapy) between the 2 groups. Our results indicated that withdrawal of ATD for 2 days is superior to 7 days in that 2 days discontinuation did not exacerbate hyperthyroidism. In order to prevent serum thyroid hormone increase after ATD withdrawal and radioiodine therapy, a 2-day ATD withdrawal period before radioiodine therapy may be useful for high-risk patients such as the elderly and patients with cardiac complications. We believe that the 2-day ATD withdrawal method may be useful for patients undergoing treatment with ATD who are to undergo radioiodine therapy.
Sumihisa Kubota; Hidemi Ohye; Genichiro Yano; Eijun Nishihara; Takumi Kudo; Mitsuru Ito; Shuji Fukata; Nobuyuki Amino; Kanji Kuma; Akira Miyauchi
Related Documents :
12091797 - One-day vs standard thyroidectomy. a perspective study of feasibility.
17179577 - Effectiveness of percutaneous ethanol injection therapy in benign nodular and cystic th...
971547 - Thyroid suppression tests during drug treatment of hyperthyroidism.
11931727 - Thymectomy for myasthenia gravis.
21501517 - Neopterin production and tryptophan degradation during 24-months therapy with interfero...
20429647 - Clinical and microbiologic follow-up evaluations after non-surgical periodontal treatme...
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article     Date:  2006-08-08
Journal Detail:
Title:  Endocrine journal     Volume:  53     ISSN:  0918-8959     ISO Abbreviation:  Endocr. J.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-10-31     Completed Date:  2007-04-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9313485     Medline TA:  Endocr J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  603-7     Citation Subset:  IM    
Kuma Hospital.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antithyroid Agents / administration & dosage*,  adverse effects*
Drug Administration Schedule
Graves Disease / drug therapy,  radiotherapy*
Hyperthyroidism / drug therapy,  radiotherapy*
Iodine Isotopes / adverse effects*,  pharmacokinetics*
Methimazole / administration & dosage*,  adverse effects*
Middle Aged
Propylthiouracil / administration & dosage*,  adverse effects*
Retrospective Studies
Thyroxine / blood
Treatment Outcome
Withholding Treatment*
Reg. No./Substance:
0/Antithyroid Agents; 0/Iodine Isotopes; 51-52-5/Propylthiouracil; 60-56-0/Methimazole; 7488-70-2/Thyroxine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A case of preclinical Cushing's syndrome associated with diurnal rhythms of ACTH and cortisol in blo...
Next Document:  Longitudinal study of patients with idiopathic isolated TSH deficiency: possible progression of pitu...